Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882

被引:122
作者
Antonini, Ninja
Jones, Heather
Horiot, Jean Claude
Poortmans, Philip
Struikmans, Henk
Van den Bogaert, Walter
Barillot, Isabelle
Fourquet, Alain
Jager, Jos
Hoogenraad, Willem
Collette, Laurence
Pierart, Marianne
Hart, Guus
Bartelink, Harry
机构
[1] Netherlands Canc Inst, Dept Radiat Oncol, NL-1066 CX Amsterdam, Netherlands
[2] Univ Penn, Dept Radiat, Philadelphia, PA 19104 USA
[3] EORTC Data Ctr, Brussels, Belgium
[4] Inst Curie, Dept Radiat Oncol, F-75231 Paris, France
[5] Radboud Univ Nijmegen Med Ctr, Dept Radiat Oncol, Nijmegen, Netherlands
[6] Ctr Georges Francois Leclerc, Dept Radiat Oncol, Dijon, France
[7] Maastro Clin Heerlen, Dept Radiat Oncol, Heerlen, Netherlands
[8] Dr B Verbeeten Inst, Dept Radiat Oncol, Tilburg, Netherlands
[9] Leiden Univ, Med Ctr, Dept Radiat Oncol, NL-2300 RA Leiden, Netherlands
[10] Univ Hosp Gasthuisberg, Dept Radiat Oncol, B-3000 Louvain, Belgium
[11] Ctr Reg Univ Cancerol Henry S Kaplan, Hop Bretonneau, Clin Oncol & Radiotherapie, Tours, France
关键词
boost; breast cancer; local control; treatment strategy; age; dose-effect;
D O I
10.1016/j.radonc.2006.09.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine whether the effect of an additional "boost" radiation after breast conservative therapy (BCT) on local control depends on age and evaluate the impact of a treatment policy with a threshold for age. Patients and methods: We used data from EORTC 22881-10882 trial, with median follow-up of 77.4 months. Patients receiving BCT and 50 Gy whole breast irradiation were randomized to no boost and 16 Gy boost (N = 5318). Results: In univariate analysis, a boost reduced local failure by a factor of 2 (P < 0.0001). Multivariate analysis showed local control increased with age (P = 0.0003). There was no evidence that the relative effect of a boost on local control depends on age (P = 0.97) However in younger patients the 5-year local failure was higher, therefore the absolute reduction was greater. If the threshold-age for boost treatment were set at 40 years, 8.4% of the study population would receive a boost, resulting in a 5-year local failure of 6.1% in the study population. Changing the threshold-age to 60 years, 67% of the study population would receive a boost and the 5-year local failure would be reduced to 4.4%. Conclusions: In younger patients a boost dose resulted in a greater absolute reduction of local failure. The relative risk reduction was however similar for all ages. Applying a treatment policy with a threshold-age of 60 would result in 0.6% increase in local failure in the total study population, while sparing the boost to 1/3 of the patients. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:265 / 271
页数:7
相关论文
共 25 条
  • [1] Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
  • [2] Radiotherapy to the conserved breast, chest wall, and regional nodes: is there a standard?
    Bartelink, H
    [J]. BREAST, 2003, 12 (06) : 475 - 482
  • [3] Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation.
    Bartelink, H
    Horiot, J
    Poortmans, P
    Struikmans, H
    Van den Bogaert, W
    Barillot, I
    Fourquet, A
    Borger, J
    Jager, J
    Hoogenraad, W
    Collette, L
    Pierart, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (19) : 1378 - 1387
  • [4] Blichert-Toft M, 1992, J Natl Cancer Inst Monogr, P19
  • [5] AGE AS A PROGNOSTIC FACTOR IN BREAST-CANCER - RELATIONSHIP TO PATHOLOGICAL AND BIOLOGIC FEATURES
    BONNIER, P
    ROMAIN, S
    CHARPIN, C
    LEJEUNE, C
    TUBIANA, N
    MARTIN, PM
    PIANA, L
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (02) : 138 - 144
  • [6] Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival
    Chang, HY
    Nuyten, DSA
    Sneddon, JB
    Hastie, T
    Tibshirani, R
    Sorlie, T
    Dai, HY
    He, YDD
    van't Veer, LJ
    Bartelink, H
    van de Rijn, M
    Brown, PO
    van de Vijver, MJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (10) : 3738 - 3743
  • [7] AGE AS PROGNOSTIC FACTOR IN PREMENOPAUSAL BREAST-CARCINOMA
    DELAROCHEFORDIERE, A
    ASSELAIN, B
    CAMPANA, F
    SCHOLL, SM
    FENTON, J
    VILCOQ, JR
    DURAND, JC
    POUILLART, P
    MAGDELENAT, H
    FOURQUET, A
    [J]. LANCET, 1993, 341 (8852) : 1039 - 1043
  • [8] *EARL BREAST CANC, 2002, LANCET, V355, P1757
  • [9] Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer
    Fisher, B
    Anderson, S
    Bryant, J
    Margolese, RG
    Deutsch, M
    Fisher, ER
    Jeong, J
    Wolmark, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (16) : 1233 - 1241
  • [10] Fodor Janos, 2005, Magy Onkol, V49, P205